Company news

Intensity Therapeutics, Inc. news in 2025

Intensity Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

December 11, 2025

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

December 5, 2025

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

December 4, 2025

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 6, 2025

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

October 31, 2025

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

October 30, 2025

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

September 10, 2025

Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

September 2, 2025

Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

August 12, 2025

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 7, 2025

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

August 4, 2025

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

June 30, 2025

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

June 11, 2025

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

June 11, 2025

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

June 11, 2025

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 29, 2025

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

May 28, 2025

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

May 6, 2025

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

April 25, 2025

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

March 13, 2025

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

January 27, 2025

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

January 9, 2025

Decks in 2025